David H. Munn

David H. Munn

Auto-generated profile, based on publicly available information

David H. Munn

Georgia Cancer Center, Augusta University, Augusta, Georgia

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Immunity
Verified
Journal Article
Closed access
NSNagendra Singh
Nagendra Singh
AGAshish Gurav
Ashish Gurav
SSSathish Sivaprakasam
Sathish Sivaprakasam
EBEvan Brady
Evan Brady
RPRavi Padia
Ravi Padia
VGVadivel Ganapathy
Vadivel Ganapathy

21 August 1998 in Science
Verified
Journal Article
Closed access
PDF file
DMDavid H. Munn
David H. Munn
MZMin Zhou
Min Zhou
JAJohn T. Attwood
John T. Attwood
IBIgor Bondarev
Igor Bondarev
SCSimon J. Conway
Simon J. Conway
AMAndrew L. Mellor
Andrew L. Mellor
In 1953 Medawar pointed out that survival of the genetically disparate (allogeneic) mammalian conceptus contradicts the laws of tissue transplantation. Rapid T cell–induced rejection of all allogeneic concepti occurred when pregnant mice were treated with a pharmacologic inhibitor of indoleamine 2,3-dioxygenase (IDO), a tryptophan-catabolizing enzyme expressed by trophoblasts and macrophages. Thus, by catabolizing tryptophan, the mammalian conceptus suppresses T cell activity and defends itself against rejection.

3 May 1999 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DMDavid H. Munn
David H. Munn
ESEbrahim Shafizadeh
Ebrahim Shafizadeh
JAJohn T. Attwood
John T. Attwood
IBIgor Bondarev
Igor Bondarev
APAchal Pashine
Achal Pashine
AMAndrew L. Mellor
Andrew L. Mellor
We have recently shown that expression of the enzyme indoleamine 2,3-dioxygenase (IDO) during murine pregnancy is required to prevent rejection of the allogeneic fetus by maternal T cells. In addition to their role in pregnancy, IDO-expressing cells are widely distributed in primary and secondary lymphoid organs. Here we show that monocytes that have differentiated under the influence of macrophage colony-stimulating factor acquire the ability to suppress T cell proliferation in vitro via rapid and selective degradation of tryptophan by IDO. IDO was induced in macrophages by a synergistic combination of the T cell–derived signals IFN-γ and CD40-ligand. Inhibition of IDO with the 1-methyl analogue of tryptophan prevented macrophage-mediated suppression. Purified T cells activated under tryptophan-deficient conditions were able to synthesize protein, enter the cell cycle, and progress normally through the initial stages of G1, including upregulation of IL-2 receptor and synthesis of IL-2. However, in the absence of tryptophan, cell cycle progression halted at a mid-G1 arrest point. Restoration of tryptophan to arrested cells was not sufficient to allow further cell cycle progression nor was costimulation via CD28. T cells could exit the arrested state only if a second round of T cell receptor signaling was provided in the presence of tryptophan. These data reveal a novel mechanism by which antigen-presenting cells can regulate T cell activation via tryptophan catabolism. We speculate that expression of IDO by certain antigen presenting cells in vivo allows them to suppress unwanted T cell responses.

1 May 2005 in Immunity
Verified
Journal Article
Closed access
DMDavid H. Munn
David H. Munn
MSMadhav D. Sharma
Madhav D. Sharma
BBBabak Baban
Babak Baban
HHHeather P. Harding
Heather P. Harding
YZYuhong Zhang
Yuhong Zhang
AMAndrew L. Mellor
Andrew L. Mellor

1 March 2016 in Trends in Immunology
Verified
Journal Article
Closed access
DMDavid H. Munn
David H. Munn
AMAndrew L. Mellor
Andrew L. Mellor

1 May 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DMDavid H. Munn
David H. Munn
AMAndrew L. Mellor
Andrew L. Mellor
Tumors arise from normal cells of the body through genetic mutation. Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; that is, it is tolerant of these antigens. This acquired state of tolerance must be overcome for cancer immunotherapy to succeed. Indoleamine 2,3-dioxygenase (IDO) is one molecular mechanism that contributes to tumor-induced tolerance. IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression. It can also function as an antagonist to other activators of antitumor immunity. Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.